Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
 Announces Annual Meeting of Stockholders - EconoTimes)
SHANGHAI, China and CUPERTINO, Calif., March 21, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Annual Meeting of Stockholders will be held on Friday, April 28, 2017. The meeting will be held at the Company’s office at 19925 Stevens Creek Blvd., Suite 100, Cupertino, California 95014 at 9:00 a.m. PDT. Stockholders of record as of March 10, 2017, the record date for the meeting, are authorized and asked to vote in the manner directed in the proxy materials.
A stockholder, once having received his/her proxy notice and access card, may view the proxy statement and related materials online or request a printed copy at www.iproxydirect.com/CBMG. Stockholders may vote online, by mail or by phone, according to the instructions on the proxy, no later than 11:59 p.m., Thursday, April 27, 2017, EDT. If your shares are held in the name of a bank, broker or other nominee, please check with your bank, broker or nominee and follow the voting instructions it provides. Please send an email to [email protected] if you have questions about the Annual Meeting or have not received your proxy notice card by post or by email.
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 408-973-7884 [email protected] Vivian Chen Managing Director Investor Relations, Citigate Dewe Rogerson +1 347 481-3711 [email protected]
